Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
DehydraTECH-liraglutide is showing apparent superiority to DehydraTECH-semaglutide Select DehydraTECH-CBD formulations are showing apparent superiority to DehydraTECH-GLP-1 at 4 and 8 weeks KELOWNA, BC / ACCESSWIRE / August 21, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received 4-week and 8-week blood glucose results from ongoing animal study WEIGHT-A24-1 (the "Study"). DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A & B) were the top performers in the Study at day 56, with blood sugar level reductions of 2.50%, 1.90% and 1.53% respectively.
Hims & Hers Health: GLP-1 Is Not The Only Tailwind In This Growth Story
Hims & Hers Health stock is up over 37% since my initial coverage, as the company is experiencing strong investor optimism from its compounded GLP-1 additions to its Weight Loss portfolio. The company reported its Q2 FY24 earnings where revenue and Adjusted EBITDA grew 52% and 270% YoY respectively, as subscribers opting for Personalized Solutions grew over 164% YoY. While Hims generated close to $15M in Q2 from GLP-1 medications, it is simultaneously innovating and expanding its personalized solutions across its tenured and new specialties.
Novo Nordisk and Eli Lilly Could Have a Big Rival in the GLP-1 Market in a Few Years
The anti-obesity market is a huge growth opportunity in healthcare. Novo Nordisk and Eli Lilly dominate it today, but it may not be long before there's more competition.
Eli Lilly's Top GLP-1 Drugs Now Account for Nearly 40% of Its Revenue, and That's Likely to Go Higher in Future Quarters
Eli Lilly's sales grew by 36% last quarter, largely due to the success of two products. The company has a promising molecule, tirzepatide, which has shown that it can help people lose significant weight.
Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Hims just reported record Revenue, Profits, and Cash Flows, signifying improving fundamentals. This was driven by robust growth in its core offerings as well as the launch of its new Weight Loss offering. Demand for Hims products is so strong that management raised Revenue guidance by more than $100M.
Hims & Hers Stock Is Looking to Cash in From the GLP-1 Hype, but Will Its Controversial Strategy Pay Off?
Hims & Hers is offering customers access to compounded GLP-1 weight loss drugs. Compounded drugs are only available when there's a shortage.
GLP: Attractive Yield And Business If Traditional Energy Production Increases
The 2024 U.S. election will impact oil and gasoline prices, affecting economic conditions and inflation. Global Partners LP focuses on traditional hydrocarbons, but has initiatives for low carbon solutions. A potential shift in U.S. energy policy post-2024 election could impact GLP's performance and the energy market.
Novo Nordisk GLP-1 drug shows encouraging signs in early stage Alzheimer's trial
A small clinical trial revealed that a weight-loss drug from the GLP-1 receptor agonist class slowed brain volume loss in people with mild Alzheimer's disease. The trial results, presented at the Alzheimer's Association International Conference, offered initial insights into how GLP-1 drugs might affect difficult-to-treat brain disorders.
Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
An older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains, according to data from a mid-stage trial. Novo Nordisk sells liraglutide under the brand names Saxenda and Victoza, which are seeing sales decline as demand for the company's weekly diabetes injection Ozempic and weight loss shot Wegovy skyrockets.
Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
Results from phase 3 RESILIENT study, using taldefgrobep alfa for the treatment of patients with spinal muscular atrophy, expected in the 2nd half of 2024. The global spinal muscular atrophy treatment market is projected to reach $8.4 billion by 2032. Preclinical model testing showed that myostatin inhibitor taldefgrobep alfa + GLP-1 inhibitor was able to show greater reductions in body weight and fat loss, compared to that of GLP-1 alone.
Hims & Hers Health: Expecting A Healthy Report
Hims & Hers Health has fallen below $20 after initial excitement over a compounded GLP-1 drug solution wanes. The health and wellness platform offers a compounded semaglutide drug at lower prices due to shortage of name-brand drugs. A short report from Hunterbrook Media questioned the business practices, but the investment story isn't based on the GLP-1 drug compound.
Hims & Hers: The Thesis Goes Far Beyond GLP-1
Hims & Hers is dedicated to telehealth and provides healthcare services remotely. It has an asset-light business model that has had extraordinary growth. The company began its growth by attacking markets sometimes overlooked by traditional medicine, such as dermatology or mental health. According to my valuation model, the stock could triple if it grows 35% annually in the coming years and reaches EBITDA margins of 25%. In my opinion, it's realistic.
